daclizumab

Type: Product

Name: daclizumab

First reported May 15 2013 - Updated May 15 2013 - 1 reports

2 Scariest Dividend Stocks in Health Care

Keep track of the stocks that matter to you.Help yourself with the Fool's FREE and easy new watchlist service today.Combining nice dividends with a growing industry that comprises roughly one-fifth of the nation's GDP should make for an attractive stock ... [Published Motley Fool - May 15 2013]

Entities: AbbVie, HUMIRA, Drugs, Dividend, PDL BioPharma Inc

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Abbvie, Inc: Steady Humira = Steady ABBV

(By Mani) Humira continues to offset the weakening of AbbVie, Inc.'s (NYSE: ABBV) other franchises, such as the lipid and HIV products, as well as AndroGel.AbbVie is a true Biopharma company with 50-60 percent of its revenues coming from Humira, a mega-blockbuster ... [Published I Stock Analyst - May 02 2013]

Entities: HUMIRA, ABBVIE INC., Phase III, daclizumab, AndroGel

First reported Apr 22 2013 - Updated Apr 23 2013 - 2 reports

Abbvie Outlook Rises

A Morgan Stanley analyst has upgraded his outlook for AbbVie Inc., expecting greater sales of the Chicago company's blockbuster anti-inflammatory drug Humira and several experimental products.Analyst David Risinger upgraded the stock to "Overweight" from ... [Published Drug Discovery and Development - Apr 23 2013]

Entities: ABBVIE INC., HUMIRA, David Risinger

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Array BioPharma Inc

Traders Recap: Biogen Idec, Array Biopharma, Universal Display, Amgen

Lakeway, NY -- (SBWIRE) -- 04/15/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-Biogen Idec Inc.(NASDAQ:BIIB) ... [Published SBWire - Apr 15 2013]

Entities: Universal Display Corporation, Array BioPharma Inc, Biogen Idec Inc, Amgen Inc

First reported Apr 13 2013 - Updated Apr 13 2013 - 1 reports

Biogen Idec Inc

The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis

-Data Demonstrated That DAC HYP Significantly Reduced Annualized Relapse Rate by up to 54 Percent at One Year--Phase 3 Study Underway to Further Assess Once-Monthly DAC HYP for Multiple Sclerosis-WESTON, MA, USA I April 4, 2013 I Today Biogen Idec (BIIB) ... [Published PipelineReview - Apr 13 2013]

Entities: Multiple Sclerosis, daclizumab, Biogen Idec Inc, The Lancet

Quotes

...Scott Brun, AbbVie's vice president, pharmaceutical development, said in a statement. "Patients who currently are unable to completely avoid gluten in their diets could potentially benefit from this promising investigational treatment."

AbbVie grabs rights to biotech startup's anti-gluten drug for $70M upfront [Published FierceBiotech - May 14 2013]

"We continue to believe that Humira simply is too well entrenched and the emerging competitors do not have meaningful advantages" BMO Capital Markets analyst Alex Arfaei wrote in a note to clients

Abbvie, Inc: Steady Humira = Steady ABBV [Published I Stock Analyst - May 02 2013]

(live-PR.com) - GlobalData has released its new Country report, "PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022" . Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neur...

Market Report, "PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 20 ... [Published Live-PR.com - May 02 2013]

The analysts wrote, "Humira continues to offset the weakening of AbbVie's other franchises, such as the lipid and HIV products as well as now AndroGel; we don't expect this to change for the foreseeable future. The recent CHMP negative opinion on Pfizer's Xeljanz (PFE) highlights the importance of having an established clinical presence in autoimmune diseases. We continue to believe that Humira simply is too well entrenched and the emerging competitors do not have meaningful advantages. Thus, Humira should continue to grow with the market as biologics gain deeper penetration in autoimmune markets driven by more aggressive treatment strategies. In the meantime, the pipeline is advancing well, with a number of meaningful data readouts expected later this year (e g., ABT-199 at ASCO, initial Hep-C phase-3 at AASLD in November) and in 2014 (e g., Daclizumab phase-3)."

AbbVie Rating Reiterated by BMO Capital Markets (ABBV) [Published American Banking News - Apr 29 2013]

More Content

sort by: Date \| Relevance
PharmaPoint Analysis: Multiple Sclerosis - US D... [Published Individual.com - May 16 2013]
PDL BioPharma Inc. (PDLI), AbbVie Inc (ABBV): T... [Published InsiderMonkey.com - May 15 2013]
2 Scariest Dividend Stocks in Health Care [Published Motley Fool - May 15 2013]
PharmaPoint: Multiple Sclerosis - US Drug Forec... [Published KOTA Territory News - May 14 2013]
AbbVie grabs rights to biotech startup's anti-g... [Published FierceBiotech - May 14 2013]
Abbvie, Inc: Steady Humira = Steady ABBV [Published I Stock Analyst - May 02 2013]
Market Report, "PharmaPoint: Multiple Sclerosis... [Published Live-PR.com - May 02 2013]
AbbVie Rating Reiterated by BMO Capital Markets... [Published American Banking News - Apr 29 2013]
UPDATE: BMO Capital Raises PT on AbbVie Followi... [Published Benzinga.com - Apr 29 2013]
Differentiation and enrichment of islet-like ce... [Published PharmCast - Apr 24 2013]
Abbvie Outlook Rises [Published Drug Discovery and Development - Apr 23 2013]
Drugmaker AbbVie rises following analyst upgrade [Published CNBC - Apr 22 2013]
Traders Recap: Biogen Idec, Array Biopharma, Un... [Published SBWire - Apr 15 2013]
The Lancet Publishes SELECT Study Evaluating Ef... [Published PipelineReview - Apr 13 2013]
The Lancet Publishes SELECT Study Evaluating Ef... [Published Business Wire Health News - Apr 04 2013]
Biogen Idec gains commercial rights of Tysabri ... [Published PharmaBiz - Apr 04 2013]
Directed engagement of activating Fc receptors [Published PharmCast - Mar 27 2013]
MS Patient Website to Provide Most Extensive On... [Published PRWeb - Mar 12 2013]
Antibody formulations [Published PharmCast - Feb 25 2013]
Purification of proteins [Published PharmCast - Feb 10 2013]
Research and Markets: Biogen-Idec's and Facet B... [Published Business Wire Health News - Jan 07 2013]
Human monoclonal antibody against coreceptors f... [Published PharmCast - Dec 04 2012]
Trends in Multiple Sclerosis Therapy Examined i... [Published PRWeb - Oct 02 2012]
i3 Analytics’ ClinicalTrials Navigator Sees A N... [Published PRWeb - Sep 13 2012]
Scientists find unique type of immune cell cont... [Published PharmaBiz - Aug 03 2012]
Treatment of multiple sclerosis using placental... [Published PharmCast - Jul 27 2012]